Claims for Patent: 5,981,214

Summary for Patent: 5,981,214

Title:	Production of proteins using homologous recombination
Abstract:	Methods and compositions are provided for expression of mammalian genes in culture. An amplifiable gene is introduced by homologous recombination in juxtaposition to a target gene, the resulting combination of amplifiable gene and target gene transferred to a convenient host and the target gene amplified by means of the amplifiable gene. The resulting expression host may then be grown in culture with enhanced expression of the target gene.
Inventor(s):	Skoultchi; Arthur I. (Larchmont, NY)
Assignee:	Cell Genesys, Inc. (Foster City, CA)
Application Number:	08/467,244
Patent Claims:	1. A method for large scale production of a mammalian target gene product in cell culture, comprising: (1) culturing a mammalian continuous cell line which was prepared by the steps of: (a) integrating, via targeted homologous recombination, a nucleotide regulatory sequence heterologous to the target gene, into the genome of a mammalian host cell, so that the integrated nucleotide regulatory sequence is operably associated with the mammalian target gene contained in the host cell genome to form a recombined mammalian target gene; and (b) transferring the recombined mammalian target gene to a mammalian continuous cell line compatible with the integrated nucleotide regulatory sequence, so that the mammalian target gene product is expressed by the mammalian continuous cell line in culture; and (2) recovering the mammalian target gene product from the cell culture. 2. The method of claim 1 in which the mammalian continuous cell line further contains an amplifiable gene operatively associated with the mammalian target gene controlled by the heterologous nucleotide regulatory sequence, and the mammalian continuous cell line is cultured under conditions that amplify the amplifiable gene and the mammalian target gene, so that expression of the mammalian target gene controlled by the heterologous nucleotide regulatory sequence is enhanced, in which the mammalian continuous cell line was prepared by: (a) integrating, via targeted homologous recombination, the amplifiable gene within an intron or proximal to the mammalian target gene contained in the mammalian host cell, so that the amplifiable gene and the heterologous regulatory sequence are operatively associated with the mammalian target gene; and (b) transferring the recombined mammalian target gene to a mammalian continuous cell line, so that the expressed mammalian target gene controlled by the heterologous regulatory sequence is amplified when the mammalian continuous cell line is cultured under conditions that amplify the amplifiable gene. 3. A method for producing a mammalian continuous cell line used for large-scale protein production in culture, comprising: (a) integrating, via targeted homologous recombination, a nucleotide regulatory sequence heterologous to a mammalian target gene contained in a mammalian host cell, so that the integrated nucleotide regulatory sequence is operably associated with the mammalian target gene to form a recombined mammalian target gene; and (b) transferring the recombined mammalian target gene to a mammalian continuous cell line compatible with the integrated nucleotide regulatory sequence, so that the mammalian target gene product is expressed by the mammalian continuous cell line in culture. 4. The method for producing the mammalian continuous cell line of claim 3, which further comprises: (a) integrating, via targeted homologous recombination, an amplifiable gene within an intron or proximal to the mammalian target gene contained in the mammalian host cell, so that the amplifiable gene and the heterologous regulatory sequence are operably associated with the mammalian target gene; and (b) transferring the recombined mammalian target gene to a mammalian continuous cell line, so that the expressed mammalian target gene controlled by the heterologous regulatory sequence is amplified when the mammalian continuous cell line is cultured under conditions that amplify the amplifiable gene. 5. The method of claim 2 or 4 in which the amplifiable gene is dihydrofolate reductase, metallothionein-I, metallothionein-II, adenosine deaminase, ornithine decarboxylase, or glutamine synthetase. 6. The method of claim 1, 2, 3 or 4 in which the mammalian host cell is a human cell. 7. The method of claim 1, 2, 3 or 4 in which the mammalian host cell is a primary cell. 8. The method of claim 7 in which the primary mammalian cell is a fibroblast, lymphocyte, epithelial or endothelial cell. 9. The method of claim 1, 2, 3 or 4 in which the mammalian target gene is a human gene. 10. The method of claim 9 in which the target gene encodes an interleukin, a growth factor, a colony stimulating factor, erythropoietin, a plasminogen activator, an enzyme, an interferon, or a receptor protein. 11. The method of claim 1, 2, 3 or 4 in which the heterologous regulatory sequence is a viral promoter or a promoter/enhancer. 12. The method of claim 11 in which the promoter/enhancer is a cytomegalovirus promoter/enhancer. 13. The method of claim 1, 2, 3 or 4 in which the mammalian continuous cell line is a Chinese hamster ovary cell line, a monkey kidney cell line, a C127 mouse fibroblast cell line, a 3T3 mouse cell line, a Vero call line or a 293 cell line. 14. A mammalian continuous cell line, the genome of which contains a heterologous genomic DNA encoding a gene product of interest operatively associated with (a) a nucleotide regulatory sequence different from the wild-type regulatory sequence normally associated with the heterologous genomic DNA, and (b) an amplifiable gene, so that expression of the heterologous genomic DNA is controlled by the regulatory sequence and is amplified when the mammalian continuous cell line is cultured under conditions that amplify the amplifiable gene. 15. The mammalian continuous cell line of claim 14 in which the heterologous genomic DNA is a human gene. 16. The mammalian continuous cell line of claim 15 in which the human gene encodes an interleukin, a growth factor, a colony stimulating factor, erythropoietin, a plasminogen activator, an enzyme, an interferon or a receptor protein. 17. The mammalian continuous cell line of claim 14 in which the regulatory sequence is a viral promoter or promoter/enhancer. 18. The mammalian continuous cell line of claim 17 in which the promoter/enhancer is a cytomegalovirus promoter/enhancer. 19. The mammalian continuous cell line of claim 14 in which the amplifiable gene is dihydrofolate reductase, metallothionain-I, Metallothionein-II, adenosine deaminase, ornithine decarboxylase, or glutamine synthetase. 20. The mammalian continuous cell line of claim 14 which is a Chinese hamster ovary cell line, a monkey kidney cell line, a C127 mouse fibroblast cell line, a 3T3 mouse cell line, a VERO cell line or a 293 cell line.

Details for Patent 5,981,214

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2016-11-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2016-11-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2016-11-09